United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$355.93 USD
+5.86 (1.67%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $355.74 -0.19 (-0.05%) 7:24 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for United Therapeutics Corporation falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2,994 | 2,839 | 1,931 | 1,835 | 1,486 |
Receivables | 279 | 220 | 199 | 157 | 151 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 112 | 102 | 94 | 87 | 93 |
Other Current Assets | 166 | 219 | 100 | 88 | 134 |
Total Current Assets | 3,551 | 3,380 | 2,324 | 2,167 | 1,865 |
Net Property & Equipment | 1,045 | 862 | 781 | 732 | 739 |
Investments & Advances | 1,910 | 1,316 | 1,650 | 1,150 | 768 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 395 | 328 | 262 | 239 | 230 |
Intangibles | 114 | 45 | 45 | 158 | 158 |
Deposits & Other Assets | 152 | 114 | 108 | 170 | 155 |
Total Assets | 7,167 | 6,045 | 5,169 | 4,615 | 3,913 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 298 | 230 | 175 | 187 | 148 |
Current Portion Long-Term Debt | 400 | 0 | 0 | 0 | 250 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 106 | 113 | 131 | 136 | 65 |
Total Current Liabilities | 804 | 343 | 305 | 323 | 463 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 300 | 800 | 800 | 800 | 600 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 78 | 105 | 105 | 97 | 70 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,182 | 1,248 | 1,210 | 1,220 | 1,133 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 2,549 | 2,388 | 2,245 | 2,149 | 2,048 |
Retained Earnings | 6,027 | 5,042 | 4,315 | 3,839 | 3,325 |
Other Equity | -13 | -56 | -23 | -14 | -14 |
Treasury Stock | 2,579 | 2,579 | 2,579 | 2,579 | 2,579 |
Total Shareholder's Equity | 5,985 | 4,797 | 3,959 | 3,395 | 2,780 |
Total Liabilities & Shareholder's Equity | 7,167 | 6,045 | 5,169 | 4,615 | 3,913 |
Total Common Equity | 5,985 | 4,797 | 3,959 | 3,395 | 2,780 |
Shares Outstanding | 46.90 | 45.50 | 45.00 | 44.40 | 43.80 |
Book Value Per Share | 127.61 | 105.42 | 87.98 | 76.47 | 63.48 |
Fiscal Year End for United Therapeutics Corporation falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2,972 | 2,708 | 2,994 | 2,876 | 2,679 |
Receivables | 291 | 307 | 279 | 259 | 273 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 137 | 120 | 112 | 104 | 103 |
Other Current Assets | 221 | 113 | 166 | 221 | 158 |
Total Current Assets | 3,620 | 3,249 | 3,551 | 3,459 | 3,213 |
Net Property & Equipment | 1,095 | 1,074 | 1,045 | 992 | 939 |
Investments & Advances | 1,330 | 1,492 | 1,910 | 2,061 | 2,024 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 396 | 396 | 395 | 326 | 326 |
Intangibles | 115 | 115 | 114 | 44 | 45 |
Deposits & Other Assets | 168 | 169 | 152 | 142 | 135 |
Total Assets | 6,723 | 6,495 | 7,167 | 7,024 | 6,681 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 325 | 305 | 298 | 333 | 292 |
Current Portion Long-Term Debt | 400 | 400 | 400 | 300 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 107 | 156 | 106 | 111 | 78 |
Total Current Liabilities | 832 | 861 | 804 | 744 | 370 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 100 | 200 | 300 | 500 | 800 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 94 | 78 | 67 | 100 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,026 | 1,157 | 1,182 | 1,312 | 1,270 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 2,543 | 2,405 | 2,549 | 2,524 | 2,498 |
Retained Earnings | 6,612 | 6,334 | 6,027 | 5,810 | 5,542 |
Other Equity | -15 | -16 | -13 | -44 | -51 |
Treasury Stock | 3,444 | 3,386 | 2,579 | 2,579 | 2,579 |
Total Shareholder's Equity | 5,697 | 5,338 | 5,985 | 5,712 | 5,411 |
Total Liabilities & Shareholder's Equity | 6,723 | 6,495 | 7,167 | 7,024 | 6,681 |
Total Common Equity | 5,697 | 5,338 | 5,985 | 5,712 | 5,411 |
Shares Outstanding | 44.40 | 44.30 | 46.90 | 46.90 | 46.90 |
Book Value Per Share | 128.32 | 120.50 | 127.61 | 121.79 | 115.37 |